A-List Executive Team, Big-Name Backers Fail to Lift Abbisko IPO
Shares of cancer drug startup, whose investors include Carlyle Group and Temasek, are down 7% a week after their trading debut Key takeaways Four rounds of fundraising together with IPO…
Recent Articles
RELATED ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Yunji rides robotics wave to Hong Kong IPO with A-list of backers
-
BRIEF: Abbisko moves into the black in 2024
2256.HK
